Table 2. NB literature review with focus on human tissue localization, pathology implication, and methods of culture and detection used for identification of NB.
Source of NB | Disease Implications | Culture Mediuma | Immuno-detection | Ref. | |||
No Serum | Medium+ FBS | Medium+ γ-FBS | Methodb | Antibodyc | |||
Kidney stones | Kidney stone formation | + | − | + | IF | 8/0, 5/2 | [5] |
Kidney stones | Kidney stone formation | + | − | − | None | None | [67] |
Kidney stones | Kidney stone formation | + | + | − | WB, OI | Polyclonal | [15] |
Kidney stones | Kidney stone formation | + | − | − | IF | 8D10 | [17] |
Kidney tissues from cancer patients | Kidney stone formation | + | + | − | ELISA, IH | 8D10 | [34] |
Kidney fluids from polycystic kidney patients | Polycystic kidney diseases | + | − | + | DB, IF | 8/0, 5/2 | [60] |
Urinary tract stone from one astronaut | Urinary tract stone formation | + | − | + | IF | 8D10 | [71] |
Urinary tract stones | None | − | + | − | IF | NM | [14] |
Urine from patients with prostatitis | Prostatitis | − | − | + | IF | 8D10 | [72] |
Calcified heart tissues | Pathological calcification | − | − | + | IF, IH | 8D10 | [16] |
Calcified heart tissues | Pathological calcification | − | − | + | None | None | [37] |
Calcified aortic heart valves | Heart valve calcification | − | − | + | None | None | [36] |
Bile and serum from cholecystolithiasis patients | Cholecystolithiasis | + | − | + | IF, ELISA | NM | [73] |
Bile from cholecystolithiasis patients | Gallstone formation | − | − | + | I-EM, IH | 8D10 | [18] |
Nasopharyngeal carcinoma cell line | Nasopharyngeal cancer | − | − | + | IF | 5/2 | [74] |
Joint fluids from arthritic patients | Arthritis | + | − | − | None | None | [75] |
Sera from normal and diseased animals | None | + | − | − | None | None | [13] |
FBS, human saliva, and dental plaque | None | + | − | + | None | None | [12] |
FBS and human serum | Pathological calcification | + | − | + | IF | 8/0, 5/2 | [2] |
FBS and cell lines | Cell culture contamination | − | + | − | None | None | [76] |
FBS | None | − | + | − | I-EM, WB | 8/0, 5/2 | [32 |
NB strains DSM 5819-21 | Pathological calcification | − | + | − | IH | 8D10 | [77] |
NB strain Seralab 901045 | None | + | + | − | WB, IF | 8D10, polyclonal | [19] |
NB strain Seralab 901045 | Pathological calcification | − | + | + | IF | 8/0, 5/2 | [69] |
NB strain Seralab 901045 and others | Pathological calcification | + | + | + | IF, WB | 8/0, 5/2 | [70] |
NB strain Seralab 901045 and tumor tissues | Intratumoral calcification | + | − | − | IF | A4002 | [78] |
DMEM was used in most studies; RPMI-1640 was used in the remaining few.
Immuno-detection: immuno-fluorescence (IF), Western blotting (WB), Ouchterlony immuno-diffusion assay (OI), enzyme-linked immuno-sorbent assay (ELISA), immuno-histochemistry (IH), dot-blotting (DB), and immuno-gold TEM (I-EM).
8D10, 8/0, 5/2, and A4002 are commercial monoclonal antibodies raised against bovine NB (Nanobac Oy). Polyclonal antibodies were also generated against different NB cultures. NM: Not mentioned.